The company raised $30 million of Series D venture funding from Ascension Ventures, GE Ventures and Healthbox on November 14, 2017, putting the company's pre-money valuation at $90 million. Safeguard Scientifics, Social Capital, Amgen Ventures, Medidata Solutions, Merck & Co. and Roche Venture Fund also participated in the round. The funds will be used to expand operations and bring precision oncology to more healthcare providers and improve patient care.
Leave a Reply ·
You must be logged in to post a comment.